Biodexa Pharmaceuticals (BDRX) Non-Current Debt (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 13 years of Non-Current Debt data on file, last reported at $16.6 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Debt rose 46.37% year-over-year to $16.6 million; the trailing twelve-month figure through Dec 2025 stood at $16.6 million (up 46.37% YoY), and the FY2025 full-year result was $16.4 million, up 45.09% from the prior year.
• Non-Current Debt climbed to $16.6 million in Q4 2025, from $668356.9 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $16.6 million in Q4 2025 to a low of $262541.9 in Q2 2024.
• A 5-year average of $8.0 million and a median of $9.3 million in 2021 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt plunged 95.65% in 2023 and surged 154.57% in 2025, its largest moves.
• Tracing BDRX's Non-Current Debt over 5 years: stood at $15.9 million in 2021, then plunged by 65.32% to $5.5 million in 2022, then jumped by 58.68% to $8.7 million in 2023, then advanced by 29.6% to $11.3 million in 2024, then jumped by 46.37% to $16.6 million in 2025.
• Business Quant data shows BDRX's Non-Current Debt at $16.6 million in Q4 2025, $668356.9 in Q2 2025, and $11.3 million in Q4 2024.